carolina.gif (1377 bytes)

NEWS SERVICES
210 Pittsboro Street, Campus Box 6210
Chapel Hill, NC  27599-6210
(919) 962-2091   FAX: (919) 962-2279
 www.unc.edu/news/

 ADVISORY

For use at 10 a.m. DST Tuesday, May 25, or thereafter May 25, 1999

 

N.C. organizations to participate in new national breast cancer study

Five N.C. medical organizations and institutions will participate in a new national breast cancer prevention trial comparing tamoxifen and raloxifene. The trial is sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the National Cancer Institute. Officials were scheduled to announce the trial today (May 25) at 10 a.m. in Washington, D.C.

Participating N.C. sites are the University of North Carolina at Chapel Hill's Lineberger Comprehensive Cancer Center; Duke Comprehensive Cancer Center in Durham; Leo Jenkins Cancer Center at East Carolina University in Greenville; Southeast Cancer Control Consortium and Wake Forest University's Comprehensive Cancer Center, both in Winston-Salem. Affiliates of these institutions are in Asheville, Charlotte, Fayetteville, Gastonia, Goldsboro, Hendersonville, Greensboro, Raleigh and Statesville, N.C.; Danville, Va; Charleston, Columbia and Florence, S.C.; Savannah, Ga; Kingsport, Tenn.; and Orlando and West Palm Beach, Fla. North Carolina has five of the 193 nucleus institutions chosen for the study, the second major breast cancer prevention trial. When these institutions select other affiliates, 400 centers in 48 states, six Canadian provinces, Puerto Rico and the District of Columbia are expected to participate.

In its first trial, the NSABP has shown that tamoxifen decreases the risk of getting breast cancer in women at high risk for the disease. The new study will examine whether raloxifene, a drug similar to tamoxifen and FDA-approved to prevent osteoporosis, also is effective in preventing invasive breast cancer in women who have not had the disease. The work also will compare benefits and side effects of the two drugs. The new trial is a randomized, double-blind study designed to include 22,000 postmenopausal women age 35 or older who are at increased risk for developing breast cancer.

For more information, click to http://cancertrials.nci.nih.gov and http://www.nsabp.pitt.edu on the World Wide Web. Both sites will feature background information, actualities, graphics and photos.

- 30 -

Contacts:

UNC Lineberger. Principal investigator: Dr. Stephen Bernard (919) 966-4431; Public affairs contact: Dianne Shaw (919) 966-5905; Prospective study participants number: (919) 966-4432

Duke. Principal investigator: Dr. Kelly Marcom (919) 684-3877; Public affairs contact: Joanne Downer (919) 660-1306; Prospective study participants number: (919) 684-3181

East Carolina. Principal investigator: Dr. Donald Lannin (252) 816-5418; Public affairs contact: Jeannine Hutson (252) 816-2481; Prospective study participants number: (252) 816-5418

Wake Forest. Principal investigator: Dr. Electra Paskett (336) 716-6946; Public affairs contact: Rae Beasley (336) 716-6878; Prospective study participants number: 336-716-1281.

Southeast Cancer Control Consortium. Principal investigator: Dr. James Atkins (919) 580-0000; Public affairs contact: Robin Burgess (336) 777-3094; Prospective study participants number: (336) 777-3094